These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 24796769)

  • 1. Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn's disease: post hoc analysis of a randomized controlled trial.
    Steenholdt C; Bendtzen K; Brynskov J; Thomsen OØ; Ainsworth MA
    Am J Gastroenterol; 2014 Jul; 109(7):1055-64. PubMed ID: 24796769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of techniques for monitoring infliximab and antibodies against infliximab in Crohn's disease.
    Steenholdt C; Ainsworth MA; Tovey M; Klausen TW; Thomsen OO; Brynskov J; Bendtzen K
    Ther Drug Monit; 2013 Aug; 35(4):530-8. PubMed ID: 23765033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in serum trough levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn's disease.
    Steenholdt C; Bendtzen K; Brynskov J; Thomsen OØ; Munck LK; Christensen LA; Pedersen G; Kjeldsen J; Ainsworth MA
    J Crohns Colitis; 2015 Mar; 9(3):238-45. PubMed ID: 25576753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of infliximab and anti-infliximab antibody measurements to evaluate and optimize efficacy and safety of infliximab maintenance therapy in Crohn's disease.
    Steenholdt C
    Dan Med J; 2013 Apr; 60(4):B4616. PubMed ID: 23651723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial.
    Steenholdt C; Brynskov J; Thomsen OØ; Munck LK; Fallingborg J; Christensen LA; Pedersen G; Kjeldsen J; Jacobsen BA; Oxholm AS; Kjellberg J; Bendtzen K; Ainsworth MA
    Gut; 2014 Jun; 63(6):919-27. PubMed ID: 23878167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Standardization of the homogeneous mobility shift assay protocol for evaluation of anti-infliximab antibodies. Application of the method to Crohn's disease patients treated with infliximab.
    Hernández-Breijo B; Chaparro M; Cano-Martínez D; Guerra I; Iborra M; Cabriada JL; Bujanda L; Taxonera C; García-Sánchez V; Marín-Jiménez I; Barreiro-de Acosta M; Vera I; Martín-Arranz MD; Mesonero F; Sempere L; Gomollón F; Hinojosa J; Gisbert JP; Guijarro LG;
    Biochem Pharmacol; 2016 Dec; 122():33-41. PubMed ID: 27664854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Magnitude of Increased Infliximab Clearance Imposed by Anti-infliximab Antibodies in Crohn's Disease Is Determined by Their Concentration.
    Edlund H; Steenholdt C; Ainsworth MA; Goebgen E; Brynskov J; Thomsen OØ; Huisinga W; Kloft C
    AAPS J; 2017 Jan; 19(1):223-233. PubMed ID: 27739011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum.
    Wang SL; Ohrmund L; Hauenstein S; Salbato J; Reddy R; Monk P; Lockton S; Ling N; Singh S
    J Immunol Methods; 2012 Aug; 382(1-2):177-88. PubMed ID: 22691619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD.
    Frederiksen MT; Ainsworth MA; Brynskov J; Thomsen OO; Bendtzen K; Steenholdt C
    Inflamm Bowel Dis; 2014 Oct; 20(10):1714-21. PubMed ID: 25069030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A rapid assay for on-site monitoring of infliximab trough levels: a feasibility study.
    Corstjens PL; Fidder HH; Wiesmeijer KC; de Dood CJ; Rispens T; Wolbink GJ; Hommes DW; Tanke HJ
    Anal Bioanal Chem; 2013 Sep; 405(23):7367-75. PubMed ID: 23836086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical effectiveness and cost-effectiveness of use of therapeutic monitoring of tumour necrosis factor alpha (TNF-α) inhibitors [LISA-TRACKER® enzyme-linked immunosorbent assay (ELISA) kits, TNF-α-Blocker ELISA kits and Promonitor® ELISA kits] versus standard care in patients with Crohn's disease: systematic reviews and economic modelling.
    Freeman K; Connock M; Auguste P; Taylor-Phillips S; Mistry H; Shyangdan D; Court R; Arasaradnam R; Sutcliffe P; Clarke A
    Health Technol Assess; 2016 Nov; 20(83):1-288. PubMed ID: 27845027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease.
    Steenholdt C; Palarasah Y; Bendtzen K; Teisner A; Brynskov J; Teisner B; Nielsen CH
    Aliment Pharmacol Ther; 2013 Jun; 37(12):1172-83. PubMed ID: 23650912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adalimumab and infliximab are equally effective for Crohn's disease in patients not previously treated with anti-tumor necrosis factor-α agents.
    Kestens C; van Oijen MG; Mulder CL; van Bodegraven AA; Dijkstra G; de Jong D; Ponsioen C; van Tuyl BA; Siersema PD; Fidder HH; Oldenburg B;
    Clin Gastroenterol Hepatol; 2013 Jul; 11(7):826-31. PubMed ID: 23376000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring functional serum antitumor necrosis factor antibody level in Crohn's disease patients who maintained and those who lost response to anti-TNF.
    Yamada A; Sono K; Hosoe N; Takada N; Suzuki Y
    Inflamm Bowel Dis; 2010 Nov; 16(11):1898-904. PubMed ID: 20310016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic drug monitoring of infliximab in inflammatory bowel disease patients in a teaching hospital setting: results of a prospective cohort study.
    Warman A; Straathof JW; Derijks LJ
    Eur J Gastroenterol Hepatol; 2015 Mar; 27(3):242-8. PubMed ID: 25569569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discrimination of Anti-drug Antibodies With Neutralizing Capacity in Infliximab- and Adalimumab-Treated Patients: Comparison of the Homogeneous Mobility Shift Assay and the Affinity Capture and Elution Assay.
    Hock BD; McKenzie JL; Goddard L; Smith SM; McEntyre CJ; Keating PE
    Ther Drug Monit; 2018 Dec; 40(6):705-715. PubMed ID: 30439789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
    Gao Q; Hogezand RA; Lamers CB; Verspaget HW
    Aliment Pharmacol Ther; 2004 Sep; 20(5):585-92. PubMed ID: 15339330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Causes of Treatment Failure in Children With Inflammatory Bowel Disease Treated With Infliximab: A Pharmacokinetic Study.
    Naviglio S; Lacorte D; Lucafò M; Cifù A; Favretto D; Cuzzoni E; Silvestri T; Pozzi Mucelli M; Radillo O; Decorti G; Fabris M; Bramuzzo M; Taddio A; Stocco G; Alvisi P; Ventura A; Martelossi S
    J Pediatr Gastroenterol Nutr; 2019 Jan; 68(1):37-44. PubMed ID: 30211845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort.
    Schnitzler F; Fidder H; Ferrante M; Noman M; Arijs I; Van Assche G; Hoffman I; Van Steen K; Vermeire S; Rutgeerts P
    Gut; 2009 Apr; 58(4):492-500. PubMed ID: 18832518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Two Different Techniques to Assess Adalimumab Trough Levels in Patients with Crohn's Disease.
    Bodini G; Giannini EG; Furnari M; Marabotto E; Baldissarro I; Del Nero L; Assandri L; Moscatelli A; Savarino V; Savarino E
    J Gastrointestin Liver Dis; 2015 Dec; 24(4):451-6. PubMed ID: 26697571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.